Compare iShares Global Clean Energy ETF (ICLN) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Summit Therapeutics Inc — how do they compare? iShares Global Clean Energy ETF trades at $18.56, while Summit Therapeutics Inc trades at $14.4 (market cap $10.48B). The key difference: iShares Global Clean Energy ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| ICLN | SMMT | |
|---|---|---|
52-Week High | $23.75 | $29.32 |
52-Week Low | $13.41 | $13.05 |
Market Cap | — | $10.48B |
Sector | — | Health |
Enterprise Value | — | $9.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN, the iShares Global Clean Energy ETF, is trading at $18.14, down 1.25% on the day, with a bearish technical outlook. The ETF provides exposure to 105 global renewable energy companies but lacks key valuation metrics like P/E and P/S ratios. Recent news highlights strong 2026 performance with over 25% gains, driven by AI-related power demand and global energy security concerns.
The outlook for ICLN is mixed, balancing strong sector tailwinds against policy risks. Investment opportunities include exposure to the growing clean energy transition, while risks involve US permit delays threatening $121 billion in projects and ongoing comparisons showing higher-yielding alternatives. The technical picture suggests near-term pressure with key support at $18.
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting ongoing volatility. The company reported a net loss of $1.08 billion for 2025, with negative ROE and ROA, but recent news includes the $105 million divestiture of ridinilazole to sharpen its oncology focus. Technical indicators are bearish, though RSI suggests potential oversold conditions. Analyst consensus remains optimistic with a $15.57 price target and 66.7% buy ratings.
The outlook hinges on clinical success of its lead oncology candidate, ivonescimab, which showed promising survival data. Key risks include high cash burn, binary drug trial outcomes, and shareholder litigation. The stock offers high-risk, high-reward potential for investors betting on pipeline success, but requires careful risk management due to financial losses and volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
